Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 4.5% – Time to Sell?

Shares of Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) fell 4.5% during mid-day trading on Tuesday. The company traded as low as $8.62 and last traded at $9.01. 1,800 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 3,836 shares. The stock had previously closed at $9.4325.

Analysts Set New Price Targets

Several analysts have recently issued reports on TLPPF shares. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Wednesday, November 4th. HC Wainwright restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, September 30th. Two analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $21.00.

View Our Latest Research Report on Telix Pharmaceuticals

Telix Pharmaceuticals Price Performance

The firm’s 50 day simple moving average is $10.29 and its 200-day simple moving average is $9.81.

About Telix Pharmaceuticals

(Get Free Report)

Telix Pharmaceuticals is an Australian biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for cancer diagnosis and treatment. Its work combines radioactive isotopes with molecules designed to target specific tumor cells. The company’s products and development programs include imaging agents for detecting and assessing cancer, as well as therapeutic candidates intended to deliver radiation to tumors. Its Illuccix product is used in prostate cancer imaging. Telix conducts commercial and development activities in markets including Australia, North America and Europe.

Recommended Stories

Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.